Alnylam publishes 3rd annual patient access philosophy report demonstrating steady access to approved therapies as company enters new geographies

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today published its third annual patient access philosophy report. this report is designed to measure alnylam's global progress against its 2017 commitments to ensuring broad access to rnai therapeutics for people who may benefit. the 2021 patient access philosophy report summarizes alnylam's latest collaborations with payer, provider, regulatory, distributor, and advocacy par
ALNY Ratings Summary
ALNY Quant Ranking